about
Total 18F-dopa PET tumour uptake reflects metabolic endocrine tumour activity in patients with a carcinoid tumour.Molecular imaging: what can be used today.Proposal for a standardized protocol for 18F-DOPA-PET (PET/CT) in congenital hyperinsulinism.6-L-18F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications.Molecular imaging in neuroendocrine tumors: molecular uptake mechanisms and clinical results.Rationale for the use of radiolabelled peptides in diagnosis and therapy.Manipulation of [11C]-5-hydroxytryptophan and 6-[18F]fluoro-3,4-dihydroxy-L-phenylalanine accumulation in neuroendocrine tumor cells.Vascular graft infection due to chronic Q fever diagnosed with fusion positron emission tomography/computed tomography.111In-octreotide is superior to 123I-metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas.Combining 6-fluoro-[18F]l-dihydroxyphenylalanine and [18F]fluoro-2-deoxy-d-glucose positron emission tomography for distinction of non-carcinoid malignancies in carcinoid patients.Better assessment of nodal metastases by PET/CT fusion compared to side-by-side PET/CT in oesophageal cancer.Carcinoid crisis after injection of 6-18F-fluorodihydroxyphenylalanine in a patient with metastatic carcinoid.18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation.Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography.Persistent aseptic meningitis due to post-surgical spinal CSF leakage: value of fused (111m)In-DTPA SPECT-CT cisternography.Clinical relevance of 18F-FDG PET and 18F-DOPA PET in recurrent medullary thyroid carcinoma.[Gastroenteropancreatic neuroendocrine tumours (carcinoid tumours): definition, clinical aspects, diagnosis and therapy]New imaging approaches to phaeochromocytomas and paragangliomas
P50
Q35201548-34F0B1DD-1520-49BD-89FF-015BE3604A4CQ36345342-A3E8CD1B-5C60-47FA-8546-055B07270EBAQ36482484-361B72FC-BC82-4D82-A969-66CA3B13FE34Q37111443-10476030-62ED-4A14-98E4-10172F0E7989Q37441673-E05B75EB-0884-443E-A3A4-C46CB85DB965Q37990410-D2C00F63-061D-431F-9CA0-22922723DFF6Q39945585-9C69EE70-20CC-4505-BBFC-BD95C655C3F1Q40443295-D1AEA12F-1ECE-4DB2-B80D-B2ECEED203C0Q44128131-673DA459-8EF3-4CBB-8CC0-1C746091DE1AQ45992393-4089C1B7-51DB-463C-BAC1-01FC29D22C55Q46481712-78F2F3F9-839C-4DF8-AE29-65BDAD0CDCE0Q46586426-DDF777E6-5C2F-4007-8C89-29758B8BC84BQ46674496-37BC0FC4-31F1-4C70-B658-669ADDB40DE0Q46694597-92ABDDD4-CBDF-4727-91A0-208AB888883EQ51202474-87486475-84D0-48C1-B789-CAFF787CEE55Q53136302-64B51F1F-9BBB-4DF0-A965-A4E910CAEF4AQ53512398-E435A909-588B-4205-A3C5-EF3D661774F0Q84576404-D6480D69-3B22-45A1-8977-1B32C78299BA
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Klaas Pieter Koopmans
@ast
Klaas Pieter Koopmans
@en
Klaas Pieter Koopmans
@es
Klaas Pieter Koopmans
@nl
Klaas Pieter Koopmans
@sl
type
label
Klaas Pieter Koopmans
@ast
Klaas Pieter Koopmans
@en
Klaas Pieter Koopmans
@es
Klaas Pieter Koopmans
@nl
Klaas Pieter Koopmans
@sl
prefLabel
Klaas Pieter Koopmans
@ast
Klaas Pieter Koopmans
@en
Klaas Pieter Koopmans
@es
Klaas Pieter Koopmans
@nl
Klaas Pieter Koopmans
@sl
P106
P31
P496
0000-0002-9684-3058